In the AURA3 study, the median PFS was significantly longer in the osimertinib group than in the chemotherapy group for patients with advanced T790M-positive NSCLC for whom disease had progressed during first-line EGFR-TKI therapy [10.1 months versus 4.4 months; HR of 0.30 (95% CI, 0.23 to 0.41); p < 0.001] [9]. Here, EGFR is linked to non-small cell lung carcinoma.